Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
ACS Nano ; 18(6): 4796-4810, 2024 Feb 13.
Article in English | MEDLINE | ID: mdl-38261783

ABSTRACT

Telomeres are nanoscale DNA-protein complexes to protect and stabilize chromosomes. The reexpression of telomerase in cancer cells is a key determinant crucial for the infinite proliferation and long-term survival of most cancer cells. However, the use of telomerase inhibitors for cancer treatment may cause problems such as poor specificity, drug resistance, and cytotoxicity. Here, we discovered a nondrug and noninvasive terahertz modulation strategy capable of the long-term suppression of cancer cells by inhibiting telomerase activity. First, we found that an optimized frequency of 33 THz photon irradiation effectively inhibited the telomerase activity by molecular dynamics simulation and frequency filtering experiments. Moreover, in vitro experiments showed that telomerase activity in 4T1 and MCF-7 cells significantly decreased by 77% and 80% respectively, after 21 days of regular 33 THz irradiation. Furthermore, two kinds of cells were found to undergo aging, apoptosis, and DNA double-strand breaks caused by telomere crisis, which seriously affected the survival of cancer cells. In addition, the tumorigenicity of 4T1 cells irradiated with 33 THz waves for 21 days in in vivo mice decreased by 70%. In summary, this study demonstrates the potential application of THz modulation in nano therapy for cancer.


Subject(s)
Neoplasms , Telomerase , Animals , Mice , Telomerase/metabolism , Enzyme Inhibitors/pharmacology , Telomere , Apoptosis , DNA
2.
Acta Pharmacol Sin ; 44(7): 1337-1349, 2023 Jul.
Article in English | MEDLINE | ID: mdl-36697977

ABSTRACT

Diabetic patients frequently experience neuropathic pain, which currently lacks effective treatments. The mechanisms underlying diabetic neuropathic pain remain unclear. The anterior cingulate cortex (ACC) is well-known to participate in the processing and transformation of pain information derived from internal and external sensory stimulation. Accumulating evidence shows that dysfunction of microglia in the central nervous system contributes to many diseases, including chronic pain and neurodegenerative diseases. In this study, we investigated the role of microglial chemokine CXCL12 and its neuronal receptor CXCR4 in diabetic pain development in a mouse diabetic model established by injection of streptozotocin (STZ). Pain sensitization was assessed by the left hindpaw pain threshold in von Frey filament test. Iba1+ microglia in ACC was examined using combined immunohistochemistry and three-dimensional reconstruction. The activity of glutamatergic neurons in ACC (ACCGlu) was detected by whole-cell recording in ACC slices from STZ mice, in vivo multi-tetrode electrophysiological and fiber photometric recordings. We showed that microglia in ACC was significantly activated and microglial CXCL12 expression was up-regulated at the 7-th week post-injection, resulting in hyperactivity of ACCGlu and pain sensitization. Pharmacological inhibition of microglia or blockade of CXCR4 in ACC by infusing minocycline or AMD3100 significantly alleviated diabetic pain through preventing ACCGlu hyperactivity in STZ mice. In addition, inhibition of microglia by infusing minocycline markedly decreased STZ-induced upregulation of microglial CXCL12. Together, this study demonstrated that microglia-mediated ACCGlu hyperactivity drives the development of diabetic pain via the CXCL12/CXCR4 signaling, thus revealing viable therapeutic targets for the treatment of diabetic pain.


Subject(s)
Diabetes Mellitus, Experimental , Neuralgia , Mice , Animals , Microglia/metabolism , Up-Regulation , Hyperalgesia/metabolism , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/metabolism , Chemokine CXCL12/pharmacology , Gyrus Cinguli/metabolism , Minocycline/pharmacology , Minocycline/therapeutic use , Spinal Cord/metabolism , Neuralgia/metabolism , Disease Models, Animal
4.
Neurotherapeutics ; 18(2): 1064-1080, 2021 04.
Article in English | MEDLINE | ID: mdl-33786807

ABSTRACT

Brain capillaries are crucial for cognitive functions by supplying oxygen and other nutrients to and removing metabolic wastes from the brain. Recent studies have demonstrated that constriction of brain capillaries is triggered by beta-amyloid (Aß) oligomers via endothelin-1 (ET1)-mediated action on the ET1 receptor A (ETRA), potentially exacerbating Aß plaque deposition, the primary pathophysiology of Alzheimer's disease (AD). However, direct evidence is still lacking whether changes in brain capillaries are causally involved in the pathophysiology of AD. Using APP/PS1 mouse model of AD (AD mice) relative to age-matched negative littermates, we identified that reductions of density and diameter of hippocampal capillaries occurred from 4 to 7 months old while Aß plaque deposition and spatial memory deficit developed at 7 months old. Notably, the injection of ET1 into the hippocampus induced early Aß plaque deposition at 5 months old in AD mice. Conversely, treatment of ferulic acid against the ETRA to counteract the ET1-mediated vasoconstriction for 30 days prevented reductions of density and diameter of hippocampal capillaries as well as ameliorated Aß plaque deposition and spatial memory deficit at 7 months old in AD mice. Thus, these data suggest that reductions of density and diameter of hippocampal capillaries are crucial for initiating Aß plaque deposition and spatial memory deficit at the early stages, implicating the development of new therapies for halting or curing memory decline in AD.


Subject(s)
Alzheimer Disease/drug therapy , Amyloid beta-Protein Precursor , Capillaries/drug effects , Cognitive Dysfunction/drug therapy , Coumaric Acids/administration & dosage , Presenilin-1 , Alzheimer Disease/genetics , Alzheimer Disease/pathology , Amyloid beta-Protein Precursor/genetics , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Capillaries/pathology , Cognitive Dysfunction/genetics , Cognitive Dysfunction/pathology , Hippocampus/blood supply , Hippocampus/drug effects , Hippocampus/pathology , Injections, Intraventricular , Male , Mice , Mice, Inbred C57BL , Mice, Transgenic , Presenilin-1/genetics
5.
Proc Natl Acad Sci U S A ; 116(9): 3799-3804, 2019 02 26.
Article in English | MEDLINE | ID: mdl-30808765

ABSTRACT

Obsessive-compulsive disorder (OCD) affects ∼1 to 3% of the world's population. However, the neural mechanisms underlying the excessive checking symptoms in OCD are not fully understood. Using viral neuronal tracing in mice, we found that glutamatergic neurons from the basolateral amygdala (BLAGlu) project onto both medial prefrontal cortex glutamate (mPFCGlu) and GABA (mPFCGABA) neurons that locally innervate mPFCGlu neurons. Next, we developed an OCD checking mouse model with quinpirole-induced repetitive checking behaviors. This model demonstrated decreased glutamatergic mPFC microcircuit activity regulated by enhanced BLAGlu inputs. Optical or chemogenetic manipulations of this maladaptive circuitry restored the behavioral response. These findings were verified in a mouse functional magnetic resonance imaging (fMRI) study, in which the BLA-mPFC functional connectivity was increased in OCD mice. Together, these findings define a unique BLAGlu→mPFCGABA→Glu circuit that controls the checking symptoms of OCD.


Subject(s)
Amygdala/metabolism , Basolateral Nuclear Complex/metabolism , Neurons/metabolism , Obsessive-Compulsive Disorder/metabolism , Amygdala/diagnostic imaging , Amygdala/physiopathology , Animals , Basolateral Nuclear Complex/diagnostic imaging , Basolateral Nuclear Complex/physiopathology , Disease Models, Animal , Glutamic Acid/metabolism , Humans , Magnetic Resonance Imaging , Mice , Neural Pathways/metabolism , Neural Pathways/physiopathology , Neurons/pathology , Obsessive-Compulsive Disorder/diagnostic imaging , Obsessive-Compulsive Disorder/physiopathology , Prefrontal Cortex/diagnostic imaging , Prefrontal Cortex/metabolism , Prefrontal Cortex/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...